Investment Rating - The investment rating for the company is "Outperform the Market" [5][30] Core Views - The company's revenue for 2024 is projected to be CNY 238.87 billion, a decrease of 5.03% year-on-year, while the net profit attributable to shareholders is expected to be CNY 2.50 billion, down 12.14% year-on-year. However, the first quarter of 2025 shows a positive trend with a revenue increase of 3.15% year-on-year to CNY 59.08 billion and a net profit increase of 11.24% year-on-year to CNY 0.98 billion [8][12] - The company is actively expanding into the health sector, establishing a dedicated department for this purpose, and has launched high-end products such as glycerol diester oil (DAG) and low GI products [2][12] - The company anticipates a moderate increase in raw material prices in 2025, which is expected to benefit its performance as the market recovers [8][12] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of CNY 238.87 billion, a decrease of 5.03% year-on-year, with a total profit of CNY 3.66 billion, an increase of 7.05% year-on-year. The net profit attributable to shareholders was CNY 2.50 billion, down 12.14% year-on-year [8][12] - The first quarter of 2025 showed a revenue increase of 3.15% year-on-year to CNY 59.08 billion and a net profit increase of 11.24% year-on-year to CNY 0.98 billion [8][12] Business Segments - The kitchen food business saw a total sales volume of 24.07 million tons in 2024, an increase of 4% year-on-year, although revenue decreased by 6% to CNY 147.6 billion due to falling raw material prices [2][12] - The feed raw materials and oil technology business experienced a sales volume of 29.65 million tons in 2024, a 10% increase year-on-year, with revenue of CNY 91.6 billion, down 10% year-on-year [3][15] Profitability and Forecasts - The company expects net profits for 2025-2027 to be CNY 3.14 billion, CNY 3.65 billion, and CNY 3.91 billion respectively, with corresponding P/E ratios of 55, 47, and 44 [3][25] - The gross margin improved to 5.35% in 2024, while the net margin slightly decreased to 1.03% [19][24]

Core Insights - The company reported a revenue of HKD 1,611.6 million for the year ending December 31, 2024, representing a year-on-year growth of 5.7% [1] - The net profit for the same period was HKD 529.2 million, with a profit attributable to shareholders of HKD 500.3 million, resulting in an earnings per share of HKD 0.60 [1] - The board proposed a final dividend of HKD 0.35 per share [1] Hong Kong Market Performance - The company achieved revenue of HKD 1,069.7 million in the Hong Kong market, marking a year-on-year increase of 16.9% [2] - Despite challenges in the retail sector, the company successfully implemented a major product strategy and enhanced market promotion, leading to a recovery in retail revenue in the second half of the year [2] - The company added 2 new retail outlets in Hong Kong during the year [2] Overseas Market Expansion - The company generated revenue of HKD 402.6 million from overseas markets, with a total of 47 retail outlets [2] - The company is focused on promoting traditional Chinese medicine culture internationally and expanding its market presence [2] - Revenue from the domestic distribution business in mainland China was HKD 139.4 million, indicating a gradual recovery [2] Production and R&D Strengthening - The company enhanced its core business by focusing on production quality management and technological innovation [3] - The production facility in Tai Po, Hong Kong, holds multiple certifications, ensuring high-quality product manufacturing [3] - The company has developed a comprehensive quality control system covering all stages from project initiation to production [3] New Product Development - The company launched several new products, including anti-aging NMN series and various herbal formulations, expanding its product matrix [4] - The company received approval for the registration of Angelica Blood Supplement Granules, further diversifying its product offerings [4] - Collaborations with universities and research institutions are ongoing to promote scientific research and product development [4] Intellectual Property Strategy - The company has accumulated 75 authorized patents and filed 8 international PCT applications as of December 31, 2024 [5] - The focus on developing new health products aligns with market trends and consumer demands [5] - The company aims to strengthen its competitive edge through robust intellectual property development [5] Brand Promotion and Market Influence - The company has intensified brand promotion efforts to enhance its international market presence [6] - Key brand activities included "Tong Ren Tang Day" and "9th Tong Ren Care Stroke Prevention," aimed at showcasing the company's cultural heritage [6] - Participation in various exhibitions has helped the company demonstrate its international development and traditional medicine culture [6] Marketing Strategies - The company has leveraged various media platforms to promote its products and traditional Chinese medicine research [7] - Marketing efforts include seasonal health education campaigns and enhanced e-commerce strategies through partnerships with major online platforms [7] - The company received multiple awards, reinforcing its brand reputation and market position [7] Future Outlook - The company anticipates new growth opportunities in the traditional Chinese medicine sector driven by supportive national policies and rising market demand [9] - Strategic initiatives for 2025 include cost reduction, efficiency enhancement, and optimizing management and investment strategies [9] - The company aims to solidify its leading position in both domestic and international markets while contributing to the sustainable development of the traditional Chinese medicine industry [9]